- Home
- DXR vs EDAP Comparison
DXR vs EDAP Comparison
Compare DXR & EDAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DXR
- EDAP
- Stock Information
- Founded
- DXR 1970
- EDAP 1979
- Country
- DXR United States
- EDAP France
- Employees
- DXR N/A
- EDAP N/A
- Industry
- DXR Medical/Dental Instruments
- EDAP Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- DXR Health Care
- EDAP Health Care
- Exchange
- DXR Nasdaq
- EDAP Nasdaq
- Market Cap
- DXR 46.9M
- EDAP 46.7M
- IPO Year
- DXR N/A
- EDAP 1997
- Fundamental
- Price
- DXR $11.41
- EDAP $2.40
- Analyst Decision
- DXR Strong Buy
- EDAP Buy
- Analyst Count
- DXR 1
- EDAP 3
- Target Price
- DXR $25.00
- EDAP $8.50
- AVG Volume (30 Days)
- DXR 7.9K
- EDAP 177.9K
- Earning Date
- DXR 01-01-0001
- EDAP 11-06-2025
- Dividend Yield
- DXR N/A
- EDAP N/A
- EPS Growth
- DXR 3.46
- EDAP N/A
- EPS
- DXR 0.36
- EDAP N/A
- Revenue
- DXR $66,306.00
- EDAP $74,008,221.00
- Revenue This Year
- DXR N/A
- EDAP N/A
- Revenue Next Year
- DXR N/A
- EDAP N/A
- P/E Ratio
- DXR $32.33
- EDAP N/A
- Revenue Growth
- DXR N/A
- EDAP 1.56
- 52 Week Low
- DXR $6.55
- EDAP $1.21
- 52 Week High
- DXR $11.70
- EDAP $3.29
- Technical
- Relative Strength Index (RSI)
- DXR 56.84
- EDAP 59.21
- Support Level
- DXR $11.10
- EDAP $2.33
- Resistance Level
- DXR $11.70
- EDAP $2.85
- Average True Range (ATR)
- DXR 0.50
- EDAP 0.30
- MACD
- DXR 0.00
- EDAP 0.02
- Stochastic Oscillator
- DXR 82.65
- EDAP 58.39
About DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.
About EDAP EDAP TMS S.A.
Edap TMS SA is a holding company operating in three divisions namely, HIFU (High-Intensity Focused Ultrasound), ESWL (Extracorporeal ShockWave Lithotripsy), and Distribution. The HIFU division develops, manufactures, and markets devices for the invasive destruction of certain types of tumors using HIFU technology. It markets three HIFU devices: the Ablatherm, Ablatherm Fusion, and the Focal One. The ESWL division is engaged in the manufacturing, marketing, and servicing of its installed base of Sonolith range of lithotripters. The Distribution division markets products that are complementary to its globalized activity such as lasers, micro-ultrasound systems, and other medical products from third parties. Its geographical segments are Asia, France, United States, and Others.